Dexcom G7 CGM OK’d; Jardiance Works for Kids; ADA’s 2023 Standards of Diabetes Care

Dexcom’s next-generation Dexcom G7 continuous glucose monitoring system was cleared by the FDA for people age 2 years and up with any type of diabetes.

In a 6-month study of people with type 2 diabetes, sticking to a low-carbohydrate, high-fat diet was better than a high-carbohydrate, low-fat diet for improving glycemic control and weight control. However, these improvements didn’t last long after the trial ended. (Annals of Internal Medicine)

Empagliflozin (Jardiance) significantly reduced HbA1c by 0.84% in adolescents ages 10 to 17 with type 2 diabetes compared with placebo by week 26 in the phase III DINAMO trial, Boehringer Ingelheim and Eli Lilly announced.

Blood pressure goals for those with diabetes were revised to target a blood pressure under 130/80 mmHg. This was just one of the new recommendations in the American Diabetes Association’s Standards of Care in Diabetes 2023. (Diabetes Care)

Avoid hypoglycemia with new diabetes technology like continuous glucose monitors, new clinical practice guidelines from the Endocrine Society recommend. (The Journal of Clinical Endocrinology & Metabolism)

A remotely delivered, self-directed behavioral lifestyle intervention helped adults with diabetes lose more weight than usual care, though the difference wasn’t “clinically important.” (JAMA)

The FDA cleared marketing of Biocorp’s smart cap sensor, Mallya, that attaches directly to insulin pens.

Amgen agreed to a $27.8 billion deal to buy Horizon Therapeutics, developer of the thyroid eye disease drug teprotumumab (Tepezza). (Reuters)